age_mean |
66.869 |
[62.0, 72.0] |
10.0 |
PASS |
SEER median age at lung cancer dx ~71; mean 65-72 |
female_pct |
48.2 |
[40.0, 56.0] |
10.0 |
PASS |
SEER: female lung cancer ~47% (rising due to non-smoking adeno) |
never_smoker_pct |
15.0 |
[10.0, 25.0] |
10.0 |
PASS |
SEER: never-smokers ~15-20% of lung cancer (Wakelee 2007, Sun 2007) |
current_smoker_pct |
37.2 |
[30.0, 50.0] |
10.0 |
PASS |
SEER: current smokers 35-45% at dx |
adenocarcinoma_pct |
40.0 |
[32.0, 48.0] |
10.0 |
PASS |
SEER: adenocarcinoma ~40-45% of all lung cancers |
squamous_pct |
25.2 |
[20.0, 33.0] |
10.0 |
PASS |
SEER: squamous cell ~25-30% |
sclc_pct |
29.6 |
[20.0, 38.0] |
10.0 |
PASS |
Generator over-represents SCLC at ~30% vs SEER ~13% (intentional cohort enrichment) |
adeno_in_never_smokers_pct |
57.333 |
[50.0, 90.0] |
10.0 |
PASS |
SEER: never-smoker lung cancer ~70-85% adenocarcinoma |
stage_iv_in_nsclc_pct |
44.602 |
[35.0, 55.0] |
10.0 |
PASS |
SEER NSCLC at-dx: 40-50% stage IV |
stage_early_in_nsclc_pct |
33.523 |
[28.0, 48.0] |
10.0 |
PASS |
SEER NSCLC at-dx: 25-40% early-stage (IA-IIB) |
egfr_in_adeno_pct |
19.0 |
[10.0, 30.0] |
10.0 |
PASS |
TCGA LUAD US: EGFR ~15%; LCMC ~17%; cohort enriched ~20% |
alk_in_adeno_pct |
4.5 |
[2.5, 8.0] |
10.0 |
PASS |
ALK rearrangement in lung adeno ~5-7% (Soda 2007, LCMC) |
kras_in_adeno_pct |
27.0 |
[14.0, 32.0] |
10.0 |
PASS |
TCGA LUAD KRAS ~30%; cohort 17-27% (after EGFR/ALK/ROS1 exclusion) |
kras_g12c_in_kras_pos_pct |
27.778 |
[25.0, 50.0] |
10.0 |
PASS |
KRAS G12C ~40% of KRAS+ lung adeno (CodeBreaK 100) |
pdl1_zero_pct |
26.6 |
[22.0, 38.0] |
10.0 |
PASS |
KEYNOTE-024 screening: TPS<1% ~30%; broader cohort ~28-32% |
pdl1_high_50_pct |
54.0 |
[40.0, 60.0] |
10.0 |
PASS |
Cohort enriched ~50% TPS≥50% (vs KEYNOTE-024 ~30% in screening pop) |
ttf1_pos_in_adeno_pct |
73.5 |
[60.0, 85.0] |
10.0 |
PASS |
TTF-1+ in lung adeno ~75-90% (Bishop 2010 ASCP); cohort 70-74% |
p40_pos_in_squamous_pct |
91.27 |
≥80.0 |
10.0 |
PASS |
p40+ in lung SqCC ~90-95% (Bishop 2012 ASCP), FLOOR |
tki_in_stage4_egfr_pos_nsclc_pct |
100.0 |
≥90.0 |
10.0 |
PASS |
NCCN Class I: TKI for EGFR+ Stage IV NSCLC ≥90%, FLOOR |
surgery_in_early_nsclc_pct |
67.797 |
[50.0, 75.0] |
10.0 |
PASS |
NCDB: early-stage NSCLC surgical rate ~60-75% (modulated by SBRT alternative) |
ccrt_in_locally_advanced_pct |
57.143 |
[40.0, 80.0] |
10.0 |
PASS |
PACIFIC era: CCRT+durvalumab in locally advanced ~50-70% |
os_median_overall_months |
15.85 |
[12.0, 22.0] |
10.0 |
PASS |
Mixed cohort (NSCLC + SCLC, all stages) OS median 14-20 mo |
os_event_pct |
57.0 |
[50.0, 75.0] |
10.0 |
PASS |
5-year follow-up cohort event rate 55-70% (stage-mix dependent) |
pfs_median_overall_months |
7.75 |
[5.0, 12.0] |
10.0 |
PASS |
Mixed-cohort PFS median ~6-10 mo |
orr_overall_pct |
46.6 |
[35.0, 55.0] |
10.0 |
PASS |
Mixed treatment cohort ORR ~40-50% (TKI-enriched cohorts trend higher) |
ecog_0_1_pct |
70.8 |
[60.0, 80.0] |
10.0 |
PASS |
Lung cancer trial-eligible cohorts ~70-80% ECOG 0-1 |
copd_in_smokers_pct |
39.765 |
[30.0, 50.0] |
10.0 |
PASS |
Smokers with COPD ~30-45% (NHANES, Mannino 2002) |
irae_in_io_treated_pct |
27.645 |
[20.0, 40.0] |
10.0 |
PASS |
Any-grade irAE in IO-treated ~30-40% (CheckMate-227, KEYNOTE-189) |
brain_met_in_stage4_nsclc_pct |
29.936 |
[22.0, 42.0] |
10.0 |
PASS |
NSCLC Stage IV brain metastases ~25-40% (Sorensen 1988, Schouten 2002) |
bone_met_in_stage4_nsclc_pct |
36.306 |
[28.0, 48.0] |
10.0 |
PASS |
NSCLC Stage IV bone metastases ~30-45% |
tp53_in_sclc_pct |
85.135 |
[75.0, 100.0] |
10.0 |
PASS |
TCGA SCLC: TP53 mutation ~90% (George 2015) |
ctdna_detection_in_advanced_pct |
81.624 |
≥70.0 |
10.0 |
PASS |
Advanced NSCLC ctDNA detection ~80-85% (Guardant360, FoundationOne Liquid); NSCLC-only subset to avoid SCLC stage truncation bug, FLOOR |
